智通财经APP获悉，科济药业-B(02171)再跌超8%，截至发稿，跌8.06%，报13港元，成交额1892.91万港元。
东方证券发布研报称，ASH 2025大会披露了BCMA TCE（T细胞接合器）特立妥单抗联合达雷妥尤单抗治疗复杂/难治性多发性骨髓瘤（R/RMM）的MajesTEC-3研究数据，疗效表现不弱于CARVYKTI，PFS率甚至更优，同时安全性良好。
该行指出，自体CAR-T凭借优异的疗效具备极大的吸引力，2025年全球销售额已接近60亿美元。近期TCE优异的数据引起市场对自体CAR-T前景的担忧，主要因为疗效接近的情况下自体CAR-T复杂的制备和使用过程，以及高昂的成本带来的价格劣势格外突出。in vivo CAR-T是解决以上问题极具潜力的方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.